Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
KLAC$129.76-19.89(-13.29%)KLA Declares Regular Cash Dividend4:30:14 PM ETKO$95.75-0.13(-0.14%)DRIVX Moves Toward Final Presale Stage, Unveils Fleet Expansion and Transparent Vesting Strategy4:19:08 PM ETCRWD$217.00-23.98(-9.95%)Why CrowdStrike and cybersecurity stocks got crunched in Thursday's rout4:12:00 PM ETLRCX$192.19-29.09(-13.15%)Lam Research Corporation Announces $25 Billion Share Repurchase Authorization and Declares Quarterly Dividend4:05:00 PM ETSKHY$124.76-18.32(-12.80%)Why SK Hynix Plunged Today4:01:39 PM ETNVDA$182.13-18.16(-9.07%)Is Nvidia Still a Millionaire-Maker Stock?3:51:00 PM ETTSLA$342.08-43.10(-11.19%)SpaceX and Tesla Stock Plunges Have Wiped About $450 Billion in Value Since the Midterms. Is It Time to Buy?3:43:35 PM ETGOOGL$280.75-8.28(-2.86%)Google plans $17 billion Wyoming data center amid rising threats of curbs3:43:13 PM ETNOW$101.20-7.71(-7.08%)Arista Networks vs. ServiceNow: Which Technology Stock Is a Better Buy for 2027?3:43:02 PM ETGOOGL$280.75-8.28(-2.86%)BREAKINGVIEWS-Global muscle will sift puny data center providers3:30:09 PM ETAMD$408.79-79.90(-16.35%)Is AMD Stock a Buy as AI Revenue Soars?3:19:00 PM ETGEV$769.00-63.51(-7.63%)GE Vernova vs. NextEra Energy: Which Industrials Stock Is a Better Buy for 2027?3:17:11 PM ETBRK-A$857,487.54-9,063.79(-1.05%)Berkshire Hathaway Reports Nov. 7 With Its Stock at a Record. Its Cash Pile Is the Number to Watch.3:17:02 PM ETC$118.48+0.68(+0.58%)UPDATE 10-Brent crude jumps, settles up over $3 after tanker attacks3:15:37 PM ETCLX$99.50+0.30(+0.30%)Global Surface Disinfectant Market to Hit US$ 7.5 Bn by 2031, Registering at 7.4% CAGR: Wissen Research3:14:00 PM ETTM$215.73+16.37(+8.21%)ERI’s John Shegerian Describes the Current State of Rare Earth Mineral Recovery at World Remanufacturing Summit in Tokyo3:09:00 PM ETMRVL$134.70-25.21(-15.77%)Marvell Just Dropped 49% in a Month: Is MRVL Stock Hopeless or Ready for a Rebound?3:03:21 PM ETSPCX$123.59-12.24(-9.01%)Bull v. Bear: SPCX Faces Uncertainty as Midterm Results Pressure TSLA Merger3:00:38 PM ETINTC$52.26-6.02(-10.33%)Intel Shares Rise 6% To Intraday High After Key Trading Signal3:00:27 PM ETAMD$408.79-79.90(-16.35%)Advanced Micro Devices vs. Taiwan Semiconductor Manufacturing: The AI Sell-Off Is Exposing a Critical Difference Investors Shouldn't Ignore for 20273:00:02 PM ETHSY$177.43+2.93(+1.68%)Hershey vs. Coca-Cola: Which Consumer Goods Stock Is a Better Buy for 2027?2:51:29 PM ETCRWD$217.00-23.98(-9.95%)CrowdStrike Stock Plummets on AI Regulation Fears2:50:42 PM ETMETA$602.76-26.91(-4.27%)Meta says US users can now video chat with their Muse AI avatar2:48:28 PM ETWFC$84.74-2.72(-3.11%)UNCF Empower Me Tour Continues in Milwaukee, WI, on Nov. 10th with College Readiness Conference, Offering Scholarships and On-Site College Admissions2:43:35 PM ET

EQ · NASDAQ

Equillium, Inc.

$1.34 -0.06 (-4.29%)

Company overview

Equillium, Inc. is a clinical-stage biotechnology company that develops and commercializes products to treat severe autoimmune and inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody targeting the novel immune checkpoint receptor CD6, which is in Phase III clinical trials for acute graft-versus-host disease; has completed a Phase Ib clinical trial for asthma; and has completed a Phase Ib clinical trial for lupus nephritis. It also develops EQ101 for cutaneous T cell lymphoma and alopecia areata, and EQ102 for various gastrointestinal diseases. The company, formerly known as Attenuate Biopharmaceuticals, Inc., changed its name to Equillium, Inc. in May 2017. Equillium was incorporated in 2017 and is headquartered in La Jolla, California.

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Market cap
$85M
Employees
35
Headquarters
La Jolla, CA
Website
equilliumbio.com
CEO
Bruce D. Steel
Listed
October 12, 2018
P/E
-3.56
Dividend yield
0.00%

Company financials

Revenue
$0.00
Gross profit
-$79,000
Operating income
-$20.4M
EBITDA
-$20.3M
Net income
-$19.1M
EPS
-$0.38
Total assets
$63.1M
Total debt
$692,000
Earnings yield
-28.08%

Revenue segmentation

By product

No annual segmentation.

By region

No geographic segmentation.

Price chart

1.061.712.352.993.64
EQ 1D NASDAQ O1.49H1.52L1.35C1.40-0.01 (-0.71%)Vol194.72K

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
View
Ticker Type Headline Source Published
EQEquillium, Inc. Press release Equillium to Participate in Upcoming Investor Conferences GlobeNewswire
EQEquillium, Inc. Press release Equillium Announces First Subject Dosed in Phase 1 Clinical Trial of EQ504 GlobeNewswire
EQEquillium, Inc. Press release Equillium Announces Poster Presentation at the 50th Anniversary La Jolla Immunology Conference GlobeNewswire
EQEquillium, Inc. Press release Equillium Receives Australian Regulatory Clearance to Initiate First-in-Human Clinical Trial of EQ504 GlobeNewswire
EQEquillium, Inc. Press release Equillium Announces Poster Presentations at the 7th International AHR Conference GlobeNewswire
EQEquillium, Inc. Stock news Equillium Eyes Q4 Phase I Start for Ulcerative Colitis Drug EQ504 MarketBeat
EQEquillium, Inc. Press release Equillium to Participate in Stifel's 2026 Virtual Immunology and Inflammation Forum GlobeNewswire
EQEquillium, Inc. Stock news EQ Resources to take 10% stake in Nevada tungsten project JV with Elmet, Blue Moon Reuters
EQEquillium, Inc. Stock news Equillium to Participate in Upcoming Investor Conferences GlobeNewswire
EQEquillium, Inc. Press release Equillium Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights GlobeNewswire
EQEquillium, Inc. Press release Bullish launches tokenized equity trading GlobeNewswire
EQEquillium, Inc. Press release Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
EQEquillium, Inc. Stock news Equillium, Inc. (EQ) Discusses Mechanistic Insights Linking AhR Signaling and miR-124 in Inflammatory Disease Transcript Seeking Alpha
EQEquillium, Inc. Stock news Equillium Links AhR Activation to miR-124 as EQ504 Heads Toward Phase 1 MarketBeat
EQEquillium, Inc. Press release Equillium to Participate in the 2026 Jefferies Global Healthcare Conference GlobeNewswire
EQEquillium, Inc. Press release Equillium to Host Virtual Investor Event to Share New Insights into the Aryl Hydrocarbon Receptor (AhR) and miR-124 Axis GlobeNewswire
EQEquillium, Inc. Press release Equillium Reports First Quarter 2026 Financial Results and Corporate Highlights GlobeNewswire
EQEquillium, Inc. Press release Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
EQEquillium, Inc. Press release Equiniti (EQ) Launches DealTrax™: A Digital-First Platform for Corporate Actions and M&A Events GlobeNewswire
EQEquillium, Inc. Press release Equillium to Participate in Oppenheimer's 2026 Innovation on the Island Event GlobeNewswire
See more
FAQ

Questions about Equillium, Inc.

What does Equillium, Inc. do?
Equillium, Inc. is a clinical-stage biotechnology company that develops and commercializes products to treat severe autoimmune and inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody targeting the novel immune checkpoint receptor CD6, which is in Phase III clinical trials for acute graft-versus-host disease; has completed a Phase Ib clinical trial for asthma; and has completed a Phase Ib clinical trial for lupus nephritis. It also develops EQ101 for cutaneous T cell lymphoma and alopecia areata, and EQ102 for various gastrointestinal diseases. The company, formerly known as Attenuate Biopharmaceuticals, Inc., changed its name to Equillium, Inc. in May 2017. Equillium was incorporated in 2017 and is headquartered in La Jolla, California.
What is EQ's market cap?
Equillium, Inc. (EQ) is a listed stock with a live quote. The latest market cap on this page is $85M.
Where is Equillium, Inc. headquartered?
Equillium, Inc. is headquartered in La Jolla, CA.
How do I get EQ news from the API?
Call GET /v1/news?tickers=EQ. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search articles since 2020 in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees articles since 2020.
How far back does EQ news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for EQ, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees articles since 2020 as headlines are ingested. A Free API key returns the last year. Pro keys search articles since 2020.
Is the EQ price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 250 REST requests a day, 1 WebSocket connection, 5 requests per second, and 2,500 WebSocket messages a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs